Back to today’s briefing

Story perspectives

Genetic Analysis AS Sees 3% Growth Amid Challenges

11/28/2025

42 4

Summary

Story summary

Genetic Analysis AS reported Q3 2025 sales growth of 3% despite currency challenges, with NOK 2.1 million in revenue.
GA-map MHI GutHealth is expected to boost growth.
Reagent kits accounted for 89% of revenues.
Gross margin fell to 64% due to U.S. tariffs, while cost controls and NOK 17.7 million cash support the outlook.

1 of 1

Story summary

Genetic Analysis AS reported Q3 2025 sales growth of 3% despite currency challenges, with NOK 2.1 million in revenue.
GA-map MHI GutHealth is expected to boost growth.
Reagent kits accounted for 89% of revenues.
Gross margin fell to 64% due to U.S. tariffs, while cost controls and NOK 17.7 million cash support the outlook.